You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
樂普醫療(300003.SZ):注射用重組A型肉毒毒素臨牀試驗申請獲得批準

格隆匯8月1日丨樂普醫療(300003.SZ)公佈,公司於今日獲悉,子公司樂普健糖藥業(重慶)有限公司(簡稱“樂普健糖”)自主研發的注射用重組A型肉毒毒素收到國家藥品監督管理局(NMPA)覈準簽發的《藥物臨牀試驗批準通知書》,由樂普健糖申報的注射用重組A型肉毒毒素(LPJT-099/DP)臨牀試驗申請獲得批準。

公司注射用重組A型肉毒毒素的氨基酸序列與公開查詢的Botox®(保妥適)和Xeomin®(思奧美)的氨基酸序列完全一致,通過重組蛋白技術進行開發生產,具有生物風險低、高純度、免疫風險低、生產效率高、產能可控等優勢。該在研項目的順利推進標誌着公司在皮膚科領域具有優異且高效的研發實力,豐富了公司皮膚科領域產品佈局,有利於增強公司在該細分領域的核心競爭力,爲公司在消費醫療市場的長期發展提供助力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account